Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects

Reuters

昨天

Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects

Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.
The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.
Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.
The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.
Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2621706953"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621706953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621706953?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621706953","market":"fut","top_or_hot":-1,"title":"Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.\n        </li>\n<li>\n          The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.\n        </li>\n<li>\n          Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.\n        </li>\n<li>\n          The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.\n        </li>\n<li>\n          Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-23 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.\n        </li>\n<li>\n          The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.\n        </li>\n<li>\n          Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.\n        </li>\n<li>\n          The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.\n        </li>\n<li>\n          Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLb4kZf4:1","article_id":"2621706953","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621706953","pubTimestamp":1774270822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIRA":"Mira Pharma"},"translate_title":"Mira Pharmaceuticals报告临床前研究发现Mira-55未显示THC样中枢神经系统副作用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":0.9},"content_text":"Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n    \n\n\n          Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.\n        \n\n          The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.\n        \n\n          Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.\n        \n\n          The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.\n        \n\n          Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}